Navigation Links
Sequenom Announces Participation At The Oppenheimer 24th Annual Healthcare Conference
Date:12/3/2013

SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Oppenheimer 24th Annual Healthcare Conference at the Crowne Plaza Hotel in New York, NY on December 10-11, 2013.

William Welch, President and COO, Paul V. Maier, Chief Financial Officer and Ronald M. Lindsay, Ph.D., EVP Strategic Planning, will present on Tuesday, December 10, 2013, beginning at 9:45 a.m. ET, and provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be an audio webcast live through the "Invest" section of the Sequenom Web site at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation. 

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sequenom to Host Analyst Day on Monday, November 14, 2011
3. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
4. Sequenom Named to NASDAQ Global Select Market
5. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
6. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
8. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
9. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
10. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
11. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):